(Q38203801)

30 August 2017

title

Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations (English)

1 reference

30 August 2017

Marinos C Dalakas

1

1 reference

30 August 2017

publication date

11 April 2014

1 reference

Journal of Clinical Immunology

30 August 2017

published in

1 reference

30 August 2017

volume

34 Suppl 1

1 reference

30 August 2017

page(s)

S120-6

1 reference

Intravenous immune globulin therapy for neurologic diseases

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Intravenous immunoglobulin in autoimmune neuromuscular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Immunology of stiff person syndrome and other GAD-associated neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Polymyositis, dermatomyositis and inclusion-body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Expression and function of the inhibitory Fcγ-receptor in CIDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Recovery of the T-cell repertoire in CIDP by IV immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Gene expression profiling in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0024-5

I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome

21 January 2018

1 reference

12 December 2020

Blockade of blocking antibodies in Guillain-Barré syndromes: "unblocking" the mystery of action of intravenous immunoglobulin

1 reference

12 December 2020

Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies

1 reference

12 December 2020

Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome

1 reference

12 December 2020

A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG

1 reference

12 December 2020

Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system

1 reference

12 December 2020

Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies

1 reference

12 December 2020

High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome

1 reference

12 December 2020

Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin

1 reference

12 December 2020

Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation"

1 reference

12 December 2020

Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules

1 reference

12 December 2020

A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis

1 reference

12 December 2020

Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies

1 reference

12 December 2020

Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle

1 reference

12 December 2020

Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome

1 reference

12 December 2020

10.1007/S10875-014-0024-5

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1053612294

0 references

1 reference